October 2020 | Hematology, Transfusion and Cell Therapy

Advanced Search

Share

English

Português

Home October 2020

Hematology, Transfusion and Cell Therapy

Hematology, Transfusion and Cell Therapy

ISSN: 2531-1379

Hematology, Transfusion and Cell Therapy is a quarterly scientific publication of the Associação Brasileira de Hematologia, Hemoterapia e Terapia Celular (ABHH), Associazione Italo-Brasiliana di Ematologia (AIBE), Eurasian Hematology Oncology Group (EHOG), and Sociedade Brasileira de Oncologia Pediátrica (SOBOPE).

Hematology, Transfusion and Cell Therapy publishes original articles, review articles and case reports covering various areas in the field of hematology and hemotherapy. The journal was previously published, until 2016, as Revista Brasileira de Hematologia e Hemoterapia.

ISSN print: 2531-1379
ISSN online: 2531-1387

Published by Elsevier Editora Ltda, Rio de Janeiro, Brazil.

See more

Indexed in:

Scopus, Medline, Directory of Open Access Journals (DOAJ), PubMed Central (PMC), Emerging Sources Citation Index (ESCI), SCImago Journal Rank (SJR), SNIP

See more

Follow us

Alert

Newsletter

Impact factor

The Impact Factor measures the average number of citations received in a particular year by papers published in the journal during the two preceding years.

© Clarivate Analytics, Journal Citation Reports 2025

See more

Impact factor 2025

1.5

Citescore

CiteScore measures average citations received per document published.

See more

Citescore 2025

2.2

SJR

SRJ is a prestige metric based on the idea that not all citations are the same. SJR uses a similar algorithm as the Google page rank; it provides a quantitative and qualitative measure of the journal's impact.

See more

SJR 2025

0.370

SNIP

SNIP measures contextual citation impact by wighting citations based on the total number of citations in a subject field.

See more

SNIP 2025

0.619

Time to first decision

The median number of days it takes for an article to go from submission to first editorial decision.

See more

Time to first decision

33 days

View more metrics

Open Access Option

Journal Information

Previous Issue | Next Issue

Issue

Cover Vol. 42. Issue S1.

Vol. 42. Issue S1.

Pages 1-78 (October 2020)

XIth Eurasian Hematology Oncology

Hematol Transfus Cell Ther. 2020;42 Supl 1:i

Open access

Share

POSTER PRESENTATIONS

Hematol Transfus Cell Ther. 2020;42 Supl 1:

Open access

Share

SPEAKER PRESENTATIONS

Hematol Transfus Cell Ther. 2020;42 Supl 1:

Open access

Share

ORAL PRESENTATIONS

Hematol Transfus Cell Ther. 2020;42 Supl 1:

Open access

Share

Welcome Address

Hematol Transfus Cell Ther. 2020;42 Supl 1:ii-iv

Open access

Share

Speaker Biographies

Hematol Transfus Cell Ther. 2020;42 Supl 1:v-xv

Open access

Share

Speaker presentations

TIM-3/Gal-9 signaling is the molecular target for human myeloid leukemia treatment

Koichi Akashi

Hematol Transfus Cell Ther. 2020;42 Supl 1:1

Open access

Share

Development of novel therapies in MDS

Kinuko Mitani

Hematol Transfus Cell Ther. 2020;42 Supl 1:1

Open access

Share

Risk scores and risk factors in CML, are they helpful?

Tomasz Sacha

Hematol Transfus Cell Ther. 2020;42 Supl 1:2

Open access

Share

Minimal residual disease detection in multiple myeloma: methods and prognostic significance

Evangelos Terpos

Hematol Transfus Cell Ther. 2020;42 Supl 1:2

Open access

Share

Treatment of relapsed, refractory multiple myeloma: focus on new drugs

Angelo Maiolino

Hematol Transfus Cell Ther. 2020;42 Supl 1:2-3

Open access

Share

Current therapy for indolent lymphomas

Guilherme Duffles Amarante, Marcia Torresan Delamain, Carmino Antonio De Souza

Hematol Transfus Cell Ther. 2020;42 Supl 1:3-5

Open access

Share

Bone marrow failure

Rodrigo T. Calado

Hematol Transfus Cell Ther. 2020;42 Supl 1:5

Open access

Share

Immunocompromised patients: prevention, diagnosis and therapy of infection

Marcio Nucci

Hematol Transfus Cell Ther. 2020;42 Supl 1:5

Open access

Share

Paroxysmal nocturnal hemoglobinuria pnh

Hanan Hamed

Hematol Transfus Cell Ther. 2020;42 Supl 1:5-6

Open access

Share

Access to cancer medicines and targeted therapies in developing countries

Zeba Aziz

Hematol Transfus Cell Ther. 2020;42 Supl 1:6

Open access

Share

Ph-positive and ph-like all: how can we further improve?

Robin Foà

Hematol Transfus Cell Ther. 2020;42 Supl 1:6-7

Open access

Share

CAR T-cell in children all

Francesco Saglio

Hematol Transfus Cell Ther. 2020;42 Supl 1:7

Open access

Share

Update on chimeric antigen receptor – T cells (CAR-T) CD19 therapy: the Sheba experience

Arnon Nagler

Hematol Transfus Cell Ther. 2020;42 Supl 1:7-8

Open access

Share

Treatment of sickle cell crises

Salam Alkindi

Hematol Transfus Cell Ther. 2020;42 Supl 1:8

Open access

Share

Secondary acute leukemia evolving from myeloproliferative neoplasm (MPN)

Tariq Mughal

Hematol Transfus Cell Ther. 2020;42 Supl 1:8-9

Open access

Share

The new European leukemianet recommendations for treating CML

Rüdiger Hehlmann

Hematol Transfus Cell Ther. 2020;42 Supl 1:9

Open access

Share

Ex vivo activation of pleural T cells in pleural malignancies

Vera S. Donnenberg, James D. Luketich, Albert D. Donnenberg

Hematol Transfus Cell Ther. 2020;42 Supl 1:9-10

Open access

Share

Are there really cancer stem cells and how do they operate?

Robert Gale

Hematol Transfus Cell Ther. 2020;42 Supl 1:10

Open access

Share

Challenges in treating solid tumors in developing countries

Adnan Abdul Jabbar

Hematol Transfus Cell Ther. 2020;42 Supl 1:10-1

Open access

Share

Lymphoblastyc lymphoma/leukemia: a single center experience

Alina Antipova, Olga Baranova

Hematol Transfus Cell Ther. 2020;42 Supl 1:11

Open access

Share

Relapsed and refractory classical Hodgkin lymphoma immunotherapy

Kirill Lepik

Hematol Transfus Cell Ther. 2020;42 Supl 1:11-2

Open access

Share

Literature review: the year in apheresis – what is new?

Joseph Schwartz

Hematol Transfus Cell Ther. 2020;42 Supl 1:12

Open access

Share

The ASFA therapeutic apheresis guidelines – 8th edition – overview with focus on hematology/oncology indications

Nancy M. Dunbar

Hematol Transfus Cell Ther. 2020;42 Supl 1:12

Open access

Share

Essential molecular characterization of AML patients

Mehmet Yilmaz

Hematol Transfus Cell Ther. 2020;42 Supl 1:12-3

Open access

Share

How clinical networking may be a powerful strategy to face the challenges faced by hematologists treating acute leukemias in the developing world. The experience of the International Consortium on Acute Leukemia (ICAL)

Eduardo M. Rego

Hematol Transfus Cell Ther. 2020;42 Supl 1:13

Open access

Share

Novel approaches to the treatment of polycythemia vera

Martin H. Ellis

Hematol Transfus Cell Ther. 2020;42 Supl 1:13-4

Open access

Share

New drugs for low grade lymphoproliferative diseases

Argiris Symeonidis

Hematol Transfus Cell Ther. 2020;42 Supl 1:14-5

Open access

Share

Which aggressive B cell lymphoma should not be treated with RCHOP?

Christian Gisselbrecht

Hematol Transfus Cell Ther. 2020;42 Supl 1:15

Open access

Share

How can we estimate early relapsed follicular lymphoma and how can we treat?

Ozan Salim

Hematol Transfus Cell Ther. 2020;42 Supl 1:15

Open access

Share

Exosomes in heme malignancies and pre-cancerous states

Rajko Kusec

Hematol Transfus Cell Ther. 2020;42 Supl 1:16

Open access

Share

Oral presentations

Isolated myeloid sarcoma causing obstructive jaundice in duodenal ampulla: a very rare case

Ömer Ekinci, Mustafa Merter, Mehmet Aslan, İlknur Calık

Hematol Transfus Cell Ther. 2020;42 Supl 1:17

Open access

Share

Blinatumomab therapy in a relapsed acute lymphoblastic leukemia with isolated radius involvement following allogeneic bone marrow transplant: a case report

İbrahim Halil Açar, Yasa Gul Mutlu, Huseyin Derya Dincyurek, Birol Guvenç

Hematol Transfus Cell Ther. 2020;42 Supl 1:18

Open access

Share

Cardiovascular risk reduction in chronic myeloid leukemia patients treated with the tyrosine kinase inhibitors

N. Lopina, I. Dmytrenko, D. Lopin, D. Hamov, I. Dyagil

Hematol Transfus Cell Ther. 2020;42 Supl 1:18-9

Open access

Share

Analysis of demographic and clinical characteristics of primary myelofibrosis and post-polycythemia vera/essential thrombocythemia myelofibrosis patients

P. Akyol, A. Yıldız, M. Albayrak, H. Afacan Öztürk, S. Maral, M. Reis Aras, F. YıLmaz, B. Saglam, ... U. Malkan

Hematol Transfus Cell Ther. 2020;42 Supl 1:19

Open access

Share

Incidence in PH-negative myeloproliferative neoplasms in armenia from 2005 to 2019

L. Sahakyan, A. Ter-Grigoryan, M. Badikyan, Y. Hakobyan, A. Saharyan, A. Shaljyan, S. Danelyan

Hematol Transfus Cell Ther. 2020;42 Supl 1:19-20

Open access

Share

The importance of next generation sequence in patients with diffuse large B cell lymphoma

A. Bolaman, I. Yavasoglu, I. Erdogdu, A. Ozcalimli

Hematol Transfus Cell Ther. 2020;42 Supl 1:20

Open access

Share

Real experience of brentuximab vedotin for cutaneous T cell lymphomas

F. Keklik Karadag, A. Arslan, T. Pashayev, N. Akad Soyer, F. Sahin, F. Vural, M. TöBü, G. Saydam

Hematol Transfus Cell Ther. 2020;42 Supl 1:20-1

Open access

Share

The prognostic impact of comorbidity, nutritional and performance status on patients with diffuse large B cell lymphoma

B. Saglam, M. Albayrak, A. Yıldız, P. Akyol, M. Tiglioglu, M. Aras, F. YıLmaz, S. Maral, H. Ozturk

Hematol Transfus Cell Ther. 2020;42 Supl 1:21

Open access

Share

Can sarcopenia be a risk factor for bleomycin toxicity?

M. Koyuncu

Hematol Transfus Cell Ther. 2020;42 Supl 1:21-2

Open access

Share

Bendamustine-bortezomib-dexamethasone (BVD) in heavily pretreated multiple myeloma: old/new in novel agents’ era

C. Cerchione, L. Catalano, D. Nappi, S. Rocco, S. Palmieri, A. Pareto, F. Pane, F. Ferrara, G. Martinelli

Hematol Transfus Cell Ther. 2020;42 Supl 1:22

Open access

Share

Efficacy and safety of daratumumab with dexamethasone in patients with relapsed/refractory multiple myeloma and severe renal impairment: results of the phase 2 dare study

E. Terpos, A. Symeonidis, S. Delimpasi, E. Zamagni, E. Katodritou, E. Rivolti, M. Kyrtsonis, D. Fotiou, ... M. Dimopoulos

Hematol Transfus Cell Ther. 2020;42 Supl 1:22-3

Open access

Share

A novel microrna signature with clinical significance in multiple myeloma

A. Papanota, P. Artemaki, P. Karousi, C. Liacos, M. Gavriatopoulou, E. Kastritis, C. Kontos, M. Dimopoulos, ... E. Terpos

Hematol Transfus Cell Ther. 2020;42 Supl 1:23-4

Open access

Share

Peripheral blood immune profiling of multiple myeloma patients at diagnosis: correlations with circulating plasma cells

K. Papadimitriou, I. Ntanasis-Stathopoulos, N. Tsakirakis, M. Gavriatopoulou, I. Kostopoulos, E. Kastritis, N. Orologas-Stavrou, M. Dimopoulos, ... E. Terpos

Hematol Transfus Cell Ther. 2020;42 Supl 1:24

Open access

Share

COVID-19 infection in cancer patients: a systematic review and meta-analysis with emphasizing the risk and prognosis stratification

G. Elgohary

Hematol Transfus Cell Ther. 2020;42 Supl 1:24-5

Open access

Share

Loading more articles...

Idiomas

Hematology, Transfusion and Cell Therapy

Home
All contents
Publish your article
About the journal
- Aims and scope
- Editorial Board
Metrics